US Stock MarketDetailed Quotes

VRTX Vertex Pharmaceuticals

Watchlist
  • 468.450
  • +2.490+0.53%
Close Aug 9 16:00 ET
  • 468.450
  • 0.0000.00%
Post 20:01 ET
120.91BMarket Cap-236590P/E (TTM)

Vertex Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-430.89%-3.75B
45.19%1.31B
-14.35%3.54B
-78.25%234.6M
32.75%1.27B
-0.47%1.13B
-5.89%899.9M
56.23%4.13B
8.38%1.08B
3.05%955.5M
Net income from continuing operations
-492.44%-3.59B
57.13%1.1B
8.96%3.62B
18.31%968.8M
11.26%1.04B
12.98%915.7M
-8.17%699.8M
41.84%3.32B
6.34%818.9M
9.23%930.5M
Operating gains losses
3,075.00%12.7M
521.88%27M
-99.60%600K
-93.33%400K
137.13%6.2M
-99.52%400K
-108.47%-6.4M
971.93%149.1M
149.59%6M
64.24%-16.7M
Depreciation and amortization
30.43%54M
37.89%53.5M
22.25%181.3M
53.65%59M
14.71%42.1M
10.99%41.4M
8.08%38.8M
18.07%148.3M
13.61%38.4M
15.77%36.7M
Deferred tax
32.73%-118.8M
-39.59%-158.3M
-94.45%-536.5M
-188.45%-131M
36.64%-115.5M
23.02%-176.6M
-821.95%-113.4M
-78.46%-275.9M
453.46%148.1M
-367.30%-182.3M
Other non cash items
-84.82%-20.7M
-283.84%-36.4M
5.47%-43.2M
-169.61%-32.3M
32.99%-19.5M
81.46%-11.2M
861.54%19.8M
-504.42%-45.7M
672.84%46.4M
-377.14%-29.1M
Change In working capital
-198.37%-241.4M
-6.91%129.3M
-177.96%-265.7M
-822.88%-838.9M
133.79%188.9M
-36.04%245.4M
523.48%138.9M
423.95%340.8M
-167.53%-90.9M
188.40%80.8M
-Change in receivables
4,758.62%135.1M
-178.01%-251.6M
76.55%-84.1M
50.98%15.4M
94.90%-6.1M
96.55%-2.9M
45.22%-90.5M
-30.54%-358.6M
123.45%10.2M
35.51%-119.5M
-Change in inventory
-47.25%-107.2M
3.03%-80.1M
-136.73%-322.9M
10.60%-70M
-263.81%-97.5M
-118.62%-72.8M
-4,230.00%-82.6M
-46.98%-136.4M
-190.00%-78.3M
-46.45%-26.8M
-Change in prepaid assets
-695.41%-155.9M
114.72%99.2M
-67.19%-545.7M
-58.63%-451.3M
4.87%-121M
-210.73%-19.6M
-31.66%46.2M
-255.56%-326.4M
-1,889.31%-284.5M
-720.65%-127.2M
-Change in payables and accrued expense
-54.15%143.2M
10.09%194.2M
-27.92%478.1M
-39.80%-388.5M
4.02%377.9M
-41.16%312.3M
274.52%176.4M
96.65%663.3M
-364.41%-277.9M
143.83%363.3M
-Change in other current liabilities
-1,003.52%-256.6M
87.47%167.6M
-58.13%208.9M
-89.71%55.5M
495.56%35.6M
159.92%28.4M
469.43%89.4M
2,869.64%498.9M
541.62%539.6M
57.75%-9M
Cash from discontinued investing activities
Operating cash flow
-430.89%-3.75B
45.19%1.31B
-14.35%3.54B
-78.25%234.6M
32.75%1.27B
-0.47%1.13B
-5.89%899.9M
56.23%4.13B
8.38%1.08B
3.05%955.5M
Investing cash flow
Cash flow from continuing investing activities
-52.58%-463.7M
-16.51%-2.14B
-878.42%-3.14B
-604.84%-886.5M
69.36%-117.7M
-394.15%-303.9M
-3,495.29%-1.83B
5.81%-321.1M
231.04%175.6M
-626.28%-384.2M
Net PPE purchase and sale
-15.77%-69M
-62.47%-68.4M
2.10%-200.4M
-72.92%-58.1M
25.09%-40.6M
-11.82%-59.6M
33.81%-42.1M
12.89%-204.7M
45.63%-33.6M
-3.44%-54.2M
Net intangibles purchase and sale
---7.7M
---180M
---58M
----
----
--0
--0
--0
----
----
Net business purchase and sale
----
----
--0
--0
----
----
----
---295.9M
--0
----
Net investment purchase and sale
-73.51%-372M
-5.39%-1.89B
-1,706.30%-2.88B
-468.26%-770.4M
-213.78%-107M
-2,514.63%-214.4M
-14,318.25%-1.79B
269.50%179.5M
389.75%209.2M
-6,720.00%-34.1M
Cash from discontinued investing activities
Investing cash flow
-52.58%-463.7M
-16.51%-2.14B
-878.42%-3.14B
-604.84%-886.5M
69.36%-117.7M
-394.15%-303.9M
-3,495.29%-1.83B
5.81%-321.1M
231.04%175.6M
-626.28%-384.2M
Financing cash flow
Cash flow from continuing financing activities
-2,172.83%-358.6M
-21.31%-357.5M
-730.43%-562.2M
-398.01%-119.8M
-174.09%-165M
-63.73%17.3M
-208.91%-294.7M
95.42%-67.7M
111.96%40.2M
90.83%-60.2M
Net issuance payments of debt
-24.55%-13.7M
-24.53%-13.2M
47.44%-43.1M
-47.83%-10.2M
77.17%-11.3M
13.39%-11M
17.83%-10.6M
-338.50%-82M
-309.09%-6.9M
-345.95%-49.5M
Net common stock issuance
-1,176.43%-400.8M
-21.81%-364.7M
-280.06%-653.7M
-7,171.43%-152.7M
-254.58%-170.2M
-613.64%-31.4M
-154.81%-299.4M
88.98%-172M
99.43%-2.1M
92.74%-48M
Proceeds from stock option exercised by employees
-6.14%55M
19.01%16.9M
-27.75%134.6M
-10.08%46.4M
-57.92%15.4M
-9.01%58.6M
-57.86%14.2M
82.65%186.3M
48.70%51.6M
165.22%36.6M
Net other financing activities
-18.18%900K
218.18%3.5M
----
----
57.14%1.1M
175.00%1.1M
-15.38%1.1M
----
----
-50.00%700K
Cash from discontinued financing activities
Financing cash flow
-2,172.83%-358.6M
-21.31%-357.5M
-730.43%-562.2M
-398.01%-119.8M
-174.09%-165M
-63.73%17.3M
-208.91%-294.7M
95.42%-67.7M
111.96%40.2M
90.83%-60.2M
Net cash flow
Beginning cash position
-1.36%9.17B
-1.33%10.37B
54.59%10.51B
21.14%11.12B
16.65%10.15B
22.25%9.3B
54.59%10.51B
13.55%6.8B
46.13%9.18B
43.37%8.7B
Current changes in cash
-639.74%-4.58B
3.35%-1.19B
-104.45%-166.6M
-159.63%-771.7M
92.86%985.7M
-24.71%847.8M
-251.69%-1.23B
353.69%3.74B
146.61%1.29B
134.88%511.1M
Effect of exchange rate changes
-125.00%-2.5M
-230.00%-15.6M
192.12%26.9M
-32.84%27.4M
41.10%-22.5M
138.61%10M
303.39%12M
-117.91%-29.2M
932.65%40.8M
-349.41%-38.2M
End cash Position
-54.78%4.59B
-1.36%9.17B
-1.33%10.37B
-1.33%10.37B
21.14%11.12B
16.65%10.15B
22.25%9.3B
54.59%10.51B
54.59%10.51B
46.13%9.18B
Free cash flow
-456.37%-3.83B
23.36%1.06B
-16.47%3.28B
-88.66%118.5M
36.23%1.23B
-1.08%1.07B
-3.90%857.8M
62.97%3.93B
11.96%1.04B
3.03%901.3M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion
--
--
--
--
--
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -430.89%-3.75B45.19%1.31B-14.35%3.54B-78.25%234.6M32.75%1.27B-0.47%1.13B-5.89%899.9M56.23%4.13B8.38%1.08B3.05%955.5M
Net income from continuing operations -492.44%-3.59B57.13%1.1B8.96%3.62B18.31%968.8M11.26%1.04B12.98%915.7M-8.17%699.8M41.84%3.32B6.34%818.9M9.23%930.5M
Operating gains losses 3,075.00%12.7M521.88%27M-99.60%600K-93.33%400K137.13%6.2M-99.52%400K-108.47%-6.4M971.93%149.1M149.59%6M64.24%-16.7M
Depreciation and amortization 30.43%54M37.89%53.5M22.25%181.3M53.65%59M14.71%42.1M10.99%41.4M8.08%38.8M18.07%148.3M13.61%38.4M15.77%36.7M
Deferred tax 32.73%-118.8M-39.59%-158.3M-94.45%-536.5M-188.45%-131M36.64%-115.5M23.02%-176.6M-821.95%-113.4M-78.46%-275.9M453.46%148.1M-367.30%-182.3M
Other non cash items -84.82%-20.7M-283.84%-36.4M5.47%-43.2M-169.61%-32.3M32.99%-19.5M81.46%-11.2M861.54%19.8M-504.42%-45.7M672.84%46.4M-377.14%-29.1M
Change In working capital -198.37%-241.4M-6.91%129.3M-177.96%-265.7M-822.88%-838.9M133.79%188.9M-36.04%245.4M523.48%138.9M423.95%340.8M-167.53%-90.9M188.40%80.8M
-Change in receivables 4,758.62%135.1M-178.01%-251.6M76.55%-84.1M50.98%15.4M94.90%-6.1M96.55%-2.9M45.22%-90.5M-30.54%-358.6M123.45%10.2M35.51%-119.5M
-Change in inventory -47.25%-107.2M3.03%-80.1M-136.73%-322.9M10.60%-70M-263.81%-97.5M-118.62%-72.8M-4,230.00%-82.6M-46.98%-136.4M-190.00%-78.3M-46.45%-26.8M
-Change in prepaid assets -695.41%-155.9M114.72%99.2M-67.19%-545.7M-58.63%-451.3M4.87%-121M-210.73%-19.6M-31.66%46.2M-255.56%-326.4M-1,889.31%-284.5M-720.65%-127.2M
-Change in payables and accrued expense -54.15%143.2M10.09%194.2M-27.92%478.1M-39.80%-388.5M4.02%377.9M-41.16%312.3M274.52%176.4M96.65%663.3M-364.41%-277.9M143.83%363.3M
-Change in other current liabilities -1,003.52%-256.6M87.47%167.6M-58.13%208.9M-89.71%55.5M495.56%35.6M159.92%28.4M469.43%89.4M2,869.64%498.9M541.62%539.6M57.75%-9M
Cash from discontinued investing activities
Operating cash flow -430.89%-3.75B45.19%1.31B-14.35%3.54B-78.25%234.6M32.75%1.27B-0.47%1.13B-5.89%899.9M56.23%4.13B8.38%1.08B3.05%955.5M
Investing cash flow
Cash flow from continuing investing activities -52.58%-463.7M-16.51%-2.14B-878.42%-3.14B-604.84%-886.5M69.36%-117.7M-394.15%-303.9M-3,495.29%-1.83B5.81%-321.1M231.04%175.6M-626.28%-384.2M
Net PPE purchase and sale -15.77%-69M-62.47%-68.4M2.10%-200.4M-72.92%-58.1M25.09%-40.6M-11.82%-59.6M33.81%-42.1M12.89%-204.7M45.63%-33.6M-3.44%-54.2M
Net intangibles purchase and sale ---7.7M---180M---58M----------0--0--0--------
Net business purchase and sale ----------0--0---------------295.9M--0----
Net investment purchase and sale -73.51%-372M-5.39%-1.89B-1,706.30%-2.88B-468.26%-770.4M-213.78%-107M-2,514.63%-214.4M-14,318.25%-1.79B269.50%179.5M389.75%209.2M-6,720.00%-34.1M
Cash from discontinued investing activities
Investing cash flow -52.58%-463.7M-16.51%-2.14B-878.42%-3.14B-604.84%-886.5M69.36%-117.7M-394.15%-303.9M-3,495.29%-1.83B5.81%-321.1M231.04%175.6M-626.28%-384.2M
Financing cash flow
Cash flow from continuing financing activities -2,172.83%-358.6M-21.31%-357.5M-730.43%-562.2M-398.01%-119.8M-174.09%-165M-63.73%17.3M-208.91%-294.7M95.42%-67.7M111.96%40.2M90.83%-60.2M
Net issuance payments of debt -24.55%-13.7M-24.53%-13.2M47.44%-43.1M-47.83%-10.2M77.17%-11.3M13.39%-11M17.83%-10.6M-338.50%-82M-309.09%-6.9M-345.95%-49.5M
Net common stock issuance -1,176.43%-400.8M-21.81%-364.7M-280.06%-653.7M-7,171.43%-152.7M-254.58%-170.2M-613.64%-31.4M-154.81%-299.4M88.98%-172M99.43%-2.1M92.74%-48M
Proceeds from stock option exercised by employees -6.14%55M19.01%16.9M-27.75%134.6M-10.08%46.4M-57.92%15.4M-9.01%58.6M-57.86%14.2M82.65%186.3M48.70%51.6M165.22%36.6M
Net other financing activities -18.18%900K218.18%3.5M--------57.14%1.1M175.00%1.1M-15.38%1.1M---------50.00%700K
Cash from discontinued financing activities
Financing cash flow -2,172.83%-358.6M-21.31%-357.5M-730.43%-562.2M-398.01%-119.8M-174.09%-165M-63.73%17.3M-208.91%-294.7M95.42%-67.7M111.96%40.2M90.83%-60.2M
Net cash flow
Beginning cash position -1.36%9.17B-1.33%10.37B54.59%10.51B21.14%11.12B16.65%10.15B22.25%9.3B54.59%10.51B13.55%6.8B46.13%9.18B43.37%8.7B
Current changes in cash -639.74%-4.58B3.35%-1.19B-104.45%-166.6M-159.63%-771.7M92.86%985.7M-24.71%847.8M-251.69%-1.23B353.69%3.74B146.61%1.29B134.88%511.1M
Effect of exchange rate changes -125.00%-2.5M-230.00%-15.6M192.12%26.9M-32.84%27.4M41.10%-22.5M138.61%10M303.39%12M-117.91%-29.2M932.65%40.8M-349.41%-38.2M
End cash Position -54.78%4.59B-1.36%9.17B-1.33%10.37B-1.33%10.37B21.14%11.12B16.65%10.15B22.25%9.3B54.59%10.51B54.59%10.51B46.13%9.18B
Free cash flow -456.37%-3.83B23.36%1.06B-16.47%3.28B-88.66%118.5M36.23%1.23B-1.08%1.07B-3.90%857.8M62.97%3.93B11.96%1.04B3.03%901.3M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion--------------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg
Concept Gene Editing
Gene Editing
Intraday+0.23%